Kura Oncology, Inc. has entered into a Co-Promotion and Medical Affairs Agreement with Kyowa Kirin, Inc. to jointly promote Kura's product candidate, ziftomenib, in the United States. Ziftomenib, a potent and selective oral menin inhibitor, is aimed at treating acute myeloid leukemia and other hematologic malignancies. Under the agreement, Kyowa Kirin US will co-promote ziftomenib and meet certain sales requirements, while Kura will lead medical affairs activities. Both companies will share costs and collaborate on the health economics and outcomes research strategy. The agreement will remain effective until mutual cessation of commercialization or the expiration of relevant patent rights and regulatory exclusivity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.